Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
EMD Serono
Seagen Inc.
Eli Lilly and Company
Pfizer
Astellas Pharma Inc
Astellas Pharma Inc
Arcus Biosciences, Inc.
Pfizer
AstraZeneca
Merck Sharp & Dohme LLC
Pfizer
Novartis
GlaxoSmithKline
Pfizer
EMD Serono
Enliven Therapeutics
Toray Industries, Inc
Jiangsu Hansoh Pharmaceutical Co., Ltd.
IGM Biosciences, Inc.
Hansoh BioMedical R&D Company
Ono Pharmaceutical Co. Ltd
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
AstraZeneca
Sumitomo Pharma Co., Ltd.
Genentech, Inc.
Hoffmann-La Roche
Shanghai JMT-Bio Inc.
Genentech, Inc.
AstraZeneca
Gilead Sciences
Lumos Pharma
Eli Lilly and Company
Bristol-Myers Squibb
TG Therapeutics, Inc.
Endocyte
Oncolytics Biotech
Eli Lilly and Company
Oncolytics Biotech
SuZhou Stainwei Biotech Inc.
PharmaEngine
Sanofi
Sanofi
Progen Pharmaceuticals
Jiangsu Simcere Pharmaceutical Co., Ltd.